reports
Teva Pharmaceutical Industries Ltd: 1 director
A director at Teva Pharmaceutical Industries Ltd sold 345,810 shares at 33.645USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Hyatt Hotels Corp: 2 directors
Two Directors at Hyatt Hotels Corp sold 2,439 shares at between 163.630USD and 166.070USD. The significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million...
Steve Madden Announces Fourth Quarter and Full Year 2025 Results
Steve Madden Announces Fourth Quarter and Full Year 2025 Results ~ Provides 2026 Revenue Outlook ~ LONG ISLAND CITY, N.Y., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Steven Madden, Ltd. (Nasdaq: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided its 2026 revenue outlook. Amounts referred to as “Adjusted” are non-GAAP measures that exclude the items defined as “Non-GAAP Adjustments” in the “Non-GAAP Reconciliation” section. Fourth Quarter 2025 Res...
Teva to Present at the Upcoming Investor Conferences in March
Teva to Present at the Upcoming Investor Conferences in March PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare ConferenceTuesday, Mar...
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...
Moody's Ratings assigns Baa2 rating to Marriott's new senior unsecured...
Moody's Ratings (Moody's) assigned a Baa2 rating to the new senior unsecured notes that Marriott International, Inc. (Marriott) announced earlier today. Marriott will use the net proceeds for general corporate purposes, which may include working capital, share repurchases or refinancing of existing ...
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...
Steve Madden Announces Fourth Quarter and Fiscal Year End 2025 Earning...
Steve Madden Announces Fourth Quarter and Fiscal Year End 2025 Earnings Release Date LONG ISLAND CITY, N.Y., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Steven Madden, Ltd. (NASDAQ: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel, today announced that the Company plans to release its fourth quarter and fiscal year end 2025 earnings results on Wednesday, February 25, 2026. Management will host a conference call to review the results at 8:30 a.m. Eastern Time. The live webcast of the management call can be accessed at the Company’s investor relations websi...
abercrombie kids Launches Baby & Toddler Collection, Expanding its Off...
abercrombie kids Launches Baby & Toddler Collection, Expanding its Offerings to Include Newborn to 5T Sizes New offering responds to customer demand and gives families one destination for children’s clothing from newborn through kids of all ages NEW ALBANY, Ohio, Feb. 11, 2026 (GLOBE NEWSWIRE) -- abercrombie kids, the children’s extension of Abercrombie & Fitch and a division of Abercrombie & Fitch Co. (NYSE: ANF), is expanding its size offerings with the launch of its new Baby & Toddler Collection. The introduction marks the brand’s first expansion into baby and toddler clothing, with ...
Abercrombie & Fitch Co: 1 director
A director at Abercrombie & Fitch Co sold 29,769 shares at 100.000USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Abercrombie & Fitch Co. to Report Fourth Quarter and Full Year 2025 Re...
Abercrombie & Fitch Co. to Report Fourth Quarter and Full Year 2025 Results on March 4, 2026 NEW ALBANY, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Wednesday, March 4, 2026, at 8:30 a.m. ET. A press release detailing the company’s fourth quarter and full year results is expected to be issued shortly after 7:30 a.m. ET. In addition, a presentation of the fourth quarter and full year results will be available on the company’s website at approximately 7:30 a.m. ET. Conference Call:...
- Si Yong Ng
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026. Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disc...
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease w...
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD programHD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms1Teva’s Honestly HD program provides educational information about HD chorea, a symptom occurring in up to 90% of people with HD,2 to help those living with the condition and their care...
Amneal to Report Fourth Quarter and Full Year 2025 Results on February...
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by clickin...
Abercrombie & Fitch Announces Plans for Super Bowl LX as “Official Fas...
Abercrombie & Fitch Announces Plans for Super Bowl LX as “Official Fashion Partner of the NFL” Week-Long Series of Activations in the San Francisco Bay Area Culminating in a Star-Studded Fashion Presentation NEW YORK and NEW ALBANY, Ohio, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Abercrombie & Fitch (“Abercrombie”), a division of Abercrombie & Fitch Co. (NYSE: ANF), and the National Football League today unveiled a series of experiences as part of Abercrombie’s first Super Bowl activation as the first league sponsor with the designation of “Official Fashion Partner of the NFL”, including curate...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.